This study provides evidence for the benefit of measuring blood indoleamine 2,3‐dioxygenase (IDO) mRNA expression and Kyn/Trp ratio, at diagnosis as a potential marker to evaluate nasopharyngeal carcinoma (NPC) progression and predict survival outcome. The gene discussed is IDO1; the disease is nasopharyngeal carcinoma.